Background-Targeting HER-2/neu with Trastuzumab has been associated with development of cardiac toxicity.

No abstract

and radiomics. 4. Interventional Oncology: Integration of Radiomics and Genomics (RadioGenomics). 5. The Cancer Genome Atlas (TCGA) and Rad-Path 2.0: Inevitable role of Interventional Oncology. 6. Future Tumor Boards: A) Treatment response stratification by RadioGenomics to decrease the number needed to treat (NNT). B) Treatment response assessment by RadioGenomics for precision/ personalized cancer management. Conclusions: Tumors are extremely heterogeneous and any successful approach to cancer management requires deep understanding of this complexity. Cancer treatment should be personalized and RadioGenomics is the inevitable part of this process. Interventional Oncology has pivotal role in this new paradigm.

No abstract

No abstract